2023 Specialty Day Access Pass-Questions and Answers

Video Transcription

Video Summary

The panel discussed meniscus and ACL injections using a 21-gauge needle, emphasizing minimal structural damage but cautioning against excessive injection volume. On PRP (platelet-rich plasma) use in osteoarthritis, it was clarified that while PRP is part of biologics and regenerative medicine broadly defined, true tissue regeneration in osteoarthritis is unproven. The speakers highlighted orthobiologics as a subset of regenerative medicine. Regarding FDA-approved placental products for treatment, none were currently known to be approved, indicating ongoing development. The session concluded with appreciation for the informative discussion on biologics and regenerative therapies.

Asset Caption

Moderator: Jason L. Dragoo, M.D., FAANA

Keywords

meniscus injections

ACL injections

platelet-rich plasma

orthobiologics

placental products FDA approval